Allos Oncologic Efaproxiral Is “Approvable” Pending Phase III ENRICH Data
Executive Summary
Approval of Allos' oncologic efaproxiral will need to await positive data from an ongoing Phase III study in patients with brain metastases originating from breast cancer, an FDA "approvable" letter states